Drug Trial Radar · NCT04650984
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
102
Planned (sponsor's estimate)
Start
Nov 29, 2017
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma patients. In the study, 102 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2). The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1).
Conditions
- Soft Tissue Sarcoma
Interventions
Onfekafusp alfaDrug
Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
DoxorubicinDrug
Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression free survival (mPFS)Time frame: From randomization up to week 72
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
Institut Bergonié
Bordeaux, France · Recruiting
Centre Georges François Leclerc
Dijon, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Not yet recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Helios Klinikum Bad Saarow
Bad Saarow, Germany · Recruiting
Charité- Universitätsmedizin Berlin
Berlin, Germany · Recruiting
Uniklinik Köln
Cologne, Germany · Recruiting
Universitätsklinikum Düsseldorf
Düsseldorf, Germany · Not yet recruiting
Universitätsklinikum Frankfurt
Frankfurt, Germany · Recruiting
Universitätsklinik Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Heidelberg University Hospital
Heidelberg, Germany · Recruiting
Universitätsmedizin der J.-G. Universität Mainz
Mainz, Germany · Recruiting
Klinik rechts der Isar
München, Germany · Recruiting
Universitaetsklinikum Muenster
Münster, Germany · Recruiting
Bologna University, Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of DIMES
Bologna, Italy · Recruiting
AOU San Luigi Gonzaga
Orbassano, Italy · Not yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Not yet recruiting
IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo
Candiolo, Torino, Italy · Recruiting
Szpital Pomorski Im. PCK
Gdynia, Poland · Not yet recruiting
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa
Warsaw, Poland · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Virgen de las Nieves
Granada, Spain · Recruiting
Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Spain · Recruiting
Hospital Miguel Servet
Zaragoza, Spain · Recruiting
Hospital Universitario Virgen de la Arrixaca
El Palmar, Murcia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.